Evidence map›Paper›PMID 40367158›Full record

ArticleScience advances2025

The role of dopaminergic medication and specific pathway alterations in idiopathic and

Alexander Balck, Max Borsche, Philip Campbell, Xi Luo, John Harvey, Theresa Brückmann, Charlotte Ludwig, Amy Harms, Katja Lohmann, Emmeline Brown and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alexander BalckInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0000-0003-3967-0282
Max BorscheInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0000-0002-9651-5986
Philip CampbellDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-1357-9256
Xi LuoDigital Twin Center, School of Medicine, University of Galway, University Rd, Galway, Ireland.
John HarveyDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-5155-2898
Theresa BrückmannInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0009-0000-5163-6816
Charlotte LudwigInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Amy HarmsDigital Twin Center, School of Medicine, University of Galway, University Rd, Galway, Ireland.ORCID 0000-0002-2931-4295
Katja LohmannInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0000-0002-5121-1460
Emmeline BrownDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Huw R MorrisDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-5473-3774
Anthony H SchapiraDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-3018-3966
Thomas HankemeierDigital Twin Center, School of Medicine, University of Galway, University Rd, Galway, Ireland.ORCID 0000-0001-7871-2073
Ronan FlemingDigital Twin Center, School of Medicine, University of Galway, University Rd, Galway, Ireland.ORCID 0000-0001-5346-9812
Silke SzymczakInstitute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.ORCID 0000-0002-8897-9035
Christine KleinInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0000-0003-2102-3431

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease, with a rapidly increasing prevalence worldwide. Biomarkers monitoring state and progression are urgently needed, and metabolomics from easily accessible biofluids holds the potential to elucidate pathophysiological underpinnings in PD. Several studies suggested metabolomic differences between patients and controls, but findings are controversial, and independent replication is scarce. We thus applied state-of-the-art, large-scale metabolomics in patients with idiopathic and monogenic PD and controls from two independent samples, analyzed by a strict meta-analysis approach. Thereby, we (i) debunked that l-Dopa medication and not disease status causes the most substantial metabolomic differences and (ii) identified polyamine metabolism alterations, partly, but not entirely associated with l-Dopa treatment. Furthermore, we found explorative but robust evidence for alterations in endocannabinoid metabolites; detected lipid metabolism alterations, highlighting potential crosslinks with alpha-synuclein pathology; and provided evidence for a metabolomic signature for the role of oxidative damage in patients with

Indexed as

Dopamine AgentsParkinson DiseaseProtein KinasesUbiquitin-Protein LigasesBiomarkersFemaleHumansLevodopaLipid MetabolismMaleMetabolomeMetabolomicsPTEN-Induced Putative KinaseBiomarkersDopamine AgentsLevodopaparkin proteinProtein KinasesPTEN-Induced Putative KinaseUbiquitin-Protein Ligases

Identifiers

PMID40367158
PMCPMC12077494

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.